The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Open accessAbstract
BACKGROUND: Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence. METHODS: Men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5 ng per milliliter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for 7 months. We then randomly assigned patients in whom the PSA level fell to 4 ng per milliliter or lower to continuous or intermittent androgen deprivation, with patients stratified according to prior or no prior hormonal therapy, performance status, and extent of disease (minimal or extensive). The coprimary objectives were to assess whether intermittent therapy was noninferior to continuous therapy with respect to survival, with a one-sided test with an upper boundary of the hazard ratio of 1.20, and whether quality of life differed between the groups 3 months after randomization. RESULTS: A total of 3040 patients were enrolled, of whom 1535 were included in the analysis: 765 randomly assigned to continuous androgen deprivation and 770 assigned to intermittent androgen deprivation. The median follow-up period was 9.8 years. Median survival was 5.8 years in the continuous-therapy group and 5.1 years in the intermittent-therapy group (hazard ratio for death with intermittent therapy, 1.10; 90% confidence interval, 0.99 to 1.23). Intermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003, respectively) at month 3 but not thereafter. There were no significant differences between the groups in the number of treatment-related high-grade adverse events. CONCLUSIONS: Our findings were statistically inconclusive. In patients with metastatic hormone-sensitive prostate cancer, the confidence interval for survival exceeded the upper boundary for noninferiority, suggesting that we cannot rule out a 20% greater risk of death with intermittent therapy than with continuous therapy, but too few events occurred to rule out significant inferiority of intermittent therapy. Intermittent therapy resulted in small improvements in quality of life. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00002651.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citationChecking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Self-citationMechanisms of Androgen-Refractory Prostate Cancer
Debes, J. D., & Tindall, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048178 · Cited by 558
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Crook, J. M., O'Callaghan, C. J., Duncan, G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S., Chin, J., Nabid, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201546 · Cited by 499
Self-citationAkakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R., & Sullivan, L. D. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z · Cited by 373
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.
Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., & Lawson, D. (1990) · PubMed · Cited by 308
Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
Larry Goldenberg, S., Bruchovsky, N., Gleave, M. E., Sullivan, L. D., & Akakura, K. (1995) · Urology · doi:10.1016/s0090-4295(99)80092-2 · Cited by 284
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Calais da Silva, F. E. C., Bono, A. V., Whelan, P., Brausi, M., Marques Queimadelos, A., Martin, J. A. P., Kirkali, Z., Calais da Silva, F. M. V., & Robertson, C. (2009) · European Urology · doi:10.1016/j.eururo.2009.02.016 · Cited by 243
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A. B., Eisenberger, M. A., Veith, R. W., Higgins, B., Skeel, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1537 · Cited by 149
Self-citationIntermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
Higano, C. S., Ellis, W., Russell, K., & Lange, P. H. (1996) · Urology · doi:10.1016/s0090-4295(96)00381-0 · Cited by 141
Self-citationde Leval, J., Boca, P., Youssef, E., Nicolas, H., Jeukenne, M., Seidel, L., Bouffioux, C., Coppens, L., Bonnet, P., Andrianne, R., et al. (2002) · Clinical Prostate Cancer · doi:10.3816/cgc.2002.n.018 · Cited by 136
Niraula, S., Le, L. W., & Tannock, I. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5492 · Cited by 121
Pattern mixture models for longitudinal quality of life studies in advanced stage disease
Ankerst, D. P., McCoy, S., & Moinpour, C. M. (2003) · Statistics in Medicine · doi:10.1002/sim.1397 · Cited by 99
Self-citationSalonen, A. J., Taari, K., Ala‐Opas, M., et al. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.01.122 · Cited by 76
Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?
Bhandari, M. S., Crook, J. M., & Hussain, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2557 · Cited by 63
Self-citationQuality of Life Assessment in Cancer Clinical Trials
Aaronson, N. K. (1990) · Springer eBooks · doi:10.1007/978-3-642-46695-3_11 · Cited by 62
Quality of life assessment in Southwest Oncology Group trials.
Moinpour, C. M., Hayden, K. A., Thompson, I. M., Feigl, P., & Metch, B. J. (1990) · PubMed · Cited by 55
Self-citationMoinpour, C. M., Triplett, J. S., McKnight, B., Lovato, L., Upchurch, C., Leichman, C. G., Muggia, F. M., Tanaka, L., James, W. A., Lennard, M., et al. (2000) · Psycho-Oncology · Cited by 54
Self-citationQuality of Life in Behavioral Medicine Research
Dimsdale, J. E., Baum, A., & Baum, A. S. (2013) · Psychology Press eBooks · doi:10.4324/9781315827438 · Cited by 31
Safety and tolerability of intermittent androgen deprivation therapy: A literature review
Gruca, D., Bacher, P. H., & Tunn, U. W. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03001.x · Cited by 23
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Moinpour, C. M., Savage, M. J., Troxel, A. B., Lovato, L., Eisenberger, M. A., Veith, R., Higgins, B., Skeel, R. T., Yee, M., Blumenstein, B. A., et al. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61702-6 · Cited by 20
Self-citation
Cited by
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Self-citationAbiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Metadata
- Authors
- Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., Small, E. J., Dawson, N. A., Donnelly, B. J., Venner, P. M., Vaishampayan, U. N., Schellhammer, P. F., Quinn, D. I., Raghavan, D., Ely, B., Moinpour, C. M., Vogelzang, N. J., & Thompson, I. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-04
- Volume
- 368
- Issue
- 14
- Pages
- 1314-1325
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081084828
- Cited by
- 580
- References
- 28
- FWCI
- 51.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.